NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.37 billion. The enterprise value is $1.63 billion.
Important Dates
The last earnings date was Tuesday, April 28, 2026, after market close.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 130.21 million shares outstanding. The number of shares has increased by 1.24% in one year.
| Current Share Class | 130.21M |
| Shares Outstanding | 130.21M |
| Shares Change (YoY) | +1.24% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 100.91% |
| Float | 118.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 43.85 |
| PS Ratio | 1.84 |
| Forward PS | 1.66 |
| PB Ratio | 1.65 |
| P/TBV Ratio | 52.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 61.10 |
| PEG Ratio | 0.85 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.19 |
| EV / EBITDA | 382.52 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.42, with a Debt / Equity ratio of 0.49.
| Current Ratio | 4.42 |
| Quick Ratio | 3.71 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | 30.78 |
| Debt / FCF | n/a |
| Interest Coverage | -22.77 |
Financial Efficiency
Return on equity (ROE) is -11.56% and return on invested capital (ROIC) is -5.72%.
| Return on Equity (ROE) | -11.56% |
| Return on Assets (ROA) | -2.64% |
| Return on Invested Capital (ROIC) | -5.72% |
| Return on Capital Employed (ROCE) | -4.93% |
| Weighted Average Cost of Capital (WACC) | 11.03% |
| Revenue Per Employee | $298,388 |
| Profits Per Employee | -$39,683 |
| Employee Count | 2,500 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 14.24 |
Taxes
| Income Tax | -2.98M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.78% in the last 52 weeks. The beta is 1.80, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.80 |
| 52-Week Price Change | +41.78% |
| 50-Day Moving Average | 8.46 |
| 200-Day Moving Average | 9.71 |
| Relative Strength Index (RSI) | 74.02 |
| Average Volume (20 Days) | 1,447,835 |
Short Selling Information
The latest short interest is 8.62 million, so 6.62% of the outstanding shares have been sold short.
| Short Interest | 8.62M |
| Short Previous Month | 9.54M |
| Short % of Shares Out | 6.62% |
| Short % of Float | 7.28% |
| Short Ratio (days to cover) | 3.41 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $745.97 million and -$99.21 million in losses. Loss per share was -$0.77.
| Revenue | 745.97M |
| Gross Profit | 321.51M |
| Operating Income | -62.24M |
| Pretax Income | -102.19M |
| Net Income | -99.21M |
| EBITDA | 4.27M |
| EBIT | -62.24M |
| Loss Per Share | -$0.77 |
Full Income StatementBalance Sheet
The company has $146.14 million in cash and $408.53 million in debt, with a net cash position of -$262.39 million or -$2.02 per share.
| Cash & Cash Equivalents | 146.14M |
| Total Debt | 408.53M |
| Net Cash | -262.39M |
| Net Cash Per Share | -$2.02 |
| Equity (Book Value) | 828.76M |
| Book Value Per Share | 6.39 |
| Working Capital | 289.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $22.42 million and capital expenditures -$27.51 million, giving a free cash flow of -$5.09 million.
| Operating Cash Flow | 22.42M |
| Capital Expenditures | -27.51M |
| Depreciation & Amortization | 66.51M |
| Net Borrowing | -201.25M |
| Free Cash Flow | -5.09M |
| FCF Per Share | -$0.04 |
Full Cash Flow StatementMargins
Gross margin is 43.10%, with operating and profit margins of -8.34% and -13.30%.
| Gross Margin | 43.10% |
| Operating Margin | -8.34% |
| Pretax Margin | -13.70% |
| Profit Margin | -13.30% |
| EBITDA Margin | 0.57% |
| EBIT Margin | -8.34% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.24% |
| Shareholder Yield | -1.24% |
| Earnings Yield | -7.24% |
| FCF Yield | -0.37% |
Analyst Forecast
The average price target for NeoGenomics is $15.06, which is 43.16% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.06 |
| Price Target Difference | 43.16% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 8.98% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.55 |
| Piotroski F-Score | 4 |
